The book “from Alchemy to IPO the business of Biotechnology” is a synopsis of the biotech industry from its inception to late 1900’s . Author Cynthia Robbins – Roth writes a first hand narration from amidst the blooming industry as she was one of the first senior scientist to be recruited by Genentech. The book gives a complete picture from the roots of biotech , the major milestones achieved and the process of getting the product out to the market. It also covers the financers, venture capitalist and the common man’s view of the biotech industry from time to time, during its progression.
My favorite part of the book is the “Roots of the biotechnology”. This part of the book talks about the events that triggered the inception of the industry and the early players who were a part of this revolution. The main trigger was the deficit of the traditional drug discovery approach where big pharmaceuticals targeted many small inorganic molecules to enzymes or cell surface receptors in test tubes and further evaluated initially successful products. This approach did not allow them to consider side effects and overall efficacy of the drug eventually leading to the failure of most drugs. The second trigger was the large amount of funding directed to cancer research by the US federal government and the National Cancer institute. Extensive research proved lymphokines as potent anti cancer agents but this discovery hit a road block as the scientific community did not know how to
4. Robert Langer, a faculty member at MIT 's prestigious Whitehead Institute, is mentioned in the article. He is a member of the Scientific Advisory Board of In Vivo Therapeutics and has a long list of accomplishments. As a faculty member should he or others who are full time faculty members at any university or college have constraints on their contributions to and activity with biotechnology companies? How might you design a fair strategic plan that would allow university research faculty to translate their work into new medical devices or practices that have both commercial and medical potential?
Biotechnology is not just a new fad. Prakash and Conko stated, “And a review of 81 separate research projects conducted over 15 years- all funded by the European Union- found that bioengineered crops and foods are at least as safe for the environment and for human consumption as conventional crops, and in some cases even safer.” (Prakash and Conko 359) This sentence summarizes an important
The author of this article, Francis Fukuyama, is fearful that biotechnology will transform human nature as it did in Brave New World. Biotechnology will shift us into
Automobiles are such a significant part of our culture today and have been for the past century as a whole. From the big screen to the pages of a book they can play seemingly important roles that cannot be ignored. Often times these vehicles can assume almost human like characteristics which can cause you, the viewer/reader, to develop a relationship with these inanimate objects whether they are the new, beautiful and sleek sports car or the old, ratty and beat-up truck. In Louise Erdrich’s “The Red Convertible” there are many occurrences in which the state of repair that the Olds is in gives you the sense that it closely represents Lyman’s current feelings towards his brother and how these feelings change and evolve throughout the length of the story.
“America 's one of the finest countries anyone ever stole” is a quote from Bobcat Goldthwait. He is an American actor, comedian, and screenwriter that refers to Christopher Columbus as the thief. Following in the European settlers footsteps, Americans had no respect for the Indians’ homes or the people themselves. Similar to Columbus and his successors, the United States government has taken Native Americans’ land. The unfairness of this injustice led to the erosion of Indians’ rights, which has ultimately threatened their safety, especially women’s. In Louise Erdrich’s novel, The Round House, she indicates that understanding the lack of safety Native women face is vital in maintaining a civil community. Louise Erdrich reveals that
In this paper I am writing on the Ventria Bioscience and the Controversy over Plant-Made Medicines Case. Ventria Bioscience is a company that is trying to commercialize pharmaceuticals made from genetically modified plants. While Ventria is gaining opposition from regulators, activist, and environmentalist; they could succeed if they use their relevant stakeholders and specific strategies, information, financial incentive, constituency building, to influence regulators.
In the article by Barry Commoner, Commoner has stated many people the genetics form of foods, how engineering food can harm human cells in their bodies, and failure that many causes. I found his essay was fascinating because it talks about science and form of genes and how they are
This was an ambitious read for me - Science has never been my strongest subject. It was therefore quite hard work at times, definitely not something to dip into casually. Nevertheless, I found it fascinating. Some things I'd heard about before, such as Graham Young the poisoner, who I remembered from the film of his life 'The Young Poisoner's Handbook'. Other things were totally new. I'm not sure how much I'll remember about all the elements, but certain 'nuggets' will stay with me. I'm glad I read it. I would only recommend it to science buffs, though, as it did get very
The patenting issue gained some attention when President Bill Clinton and Prime Minster Tony Blair jointly called for the release of raw genetic data into the public domain (CQ 405). I will argue in this paper that the aggressive competition among biotechnology firms to patent genes is
Students should see that the risks of the biotech business are driving all of MoGen’s financial decisions: debt policy, dividend policy, and share repurchase program. Debt is relatively low because higher debt levels would result in debt rating decreases and therefore higher interest rates. Similarly, the company chooses to pay no dividends because of the risk of being forced to cut the dividend during the difficult times that invariably arise in a biotech business. Students should realize that a share repurchase program is a very good match for a biotech company like MoGen. The company can distribute cash to its shareholders when profits allow, but without making an explicit (debt) or implicit (dividends) promise to the market.
In his journal his purpose is to persuade consumers against GE technology and all it entails. In detail, he goes over the background of the technology and about its’ revolutionary stage. His argument pertains to the fact that no one is educated enough and those that are cannot provide the answers that are necessary when dealing with humanity and its’ wellness. He continues with describing the inheritance danger, toxins and poisons it creates, and about the effect this technology has on the well-being of humans or the environment. This source is also from a Gale learning database in which the information is presented as a scholarly journal. The information cited in the journal are also scholarly or peer-reviewed and contain case studies that help to convey the factual base of the information provided. This source is like other sources that also argue against the dangerous concept of using biotechnology methods. Though the source is credible, questions must arise about the case studies and information provided in which is not as accurate as the journal itself. In other words, the journal was published in 2012, yet the information concluded from the case studies are outdated from 1989- 2000. A person may wonder why the author is using old case studies that are almost non-relevant in the new time frame and era of the technology itself. I plan to use this source in my writing to further explain the need for more case studies and testing with genetical engineering. Also, to give the reader an opportunity to research and find out more up to date information pertaining to the
- The biotech industry is a very uncertain environment top operate in. Giving a quantative planning can create a false sense of accuracy. That way a planning can lose much of it’s added value and confidence in planning might even disappear altogether. Strong points in Amgen’s planning is that the company focuses mainly on qualitative aspects. It should be remarked however that Amgen is in the luxurious situation that because of two very successful products she is not (totally) dependent on external investments.
The process of life has always intrigued me. From the abundance of technology being created every day to new cures battling new diseases, the world of biology is continually changing. I have always dreamt of being part of a field whose main purpose is to help others and to improve the world around us; to me that is Biotechnology. Biotechnology is the field for future innovations that benefits an individual, but also the society.
A chip that slips in under the skin to track a person’s critical information such as heart rate, pulse, temperature and other signs is currently being created and tested by Bio-hackers. Another Bio-hacker is developing crops that can resist cold temperatures such as orange crops. Biohackers are making a difference today with their eyes on tomorrow. Bio-hackers are tinkering with the DNA of existing organisms to create new ones and will lead to innovations of a biological nature (Economist.com).Many of today’s innovators began as hackers in their garages or in temporary labs set up in a high school science lab. Innovators such as Thomas Edison, companies such as Hewlett-Packard and Google were hackers working in their garages or workshops. What positive changes will Bio-hackers or innovators of today create for tomorrow? Bio-hackers are making positive changes in today’s and tomorrow’s world through by developing solutions for imperative issues in our environment, our food and our own health.
7/2/2010- The media becomes alerted about Sanofi wishing to purchase a U.S. biotech company as rumors circulate about Genzyme.